Diazyme Laboratories, Inc. Announces FDA 510(k) Clearance for Lipoprotein(a) Molarity AssayPOWAY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Diazyme Lipoprotein(a) Molarity Assay. This clearance enables clinical laboratories to use the assay for the quantitative determination of lipoprotein-Lp(a) levels in human serum and plasma, reported in molar units (nmol/L).
